What is OraSure Technologies's market cap?

OraSure Technologies (OSUR) has a market capitalization of $272.6M and trades on NASDAQ.

What is OraSure Technologies's revenue and profitability?

OraSure Technologies generated $113.0M in trailing twelve-month revenue with a net loss of $75.1M, representing a net margin of -66.4%. Gross margin stands at 42.2%, with free cash flow of -$47.9M. These figures are based on the Q1 2026 filing.

Who are OraSure Technologies's competitors?

OraSure Technologies's key competitors include QuidelOrtho, Abbott Laboratories, Danaher Corporation, and others. These companies compete in similar markets and product categories.

Who does OraSure Technologies partner with?

OraSure Technologies's notable partners include Walmart, Amazon, Diagnostics Direct, and others.

What subsidiaries does OraSure Technologies have?

OraSure Technologies's subsidiaries include BioMedomics, Inc., Sherlock.

Where is OraSure Technologies headquartered?

OraSure Technologies is headquartered in United States of America and employs approximately 638 people. It has been publicly traded since 1986.

OraSure Technologies

OSUR

OraSure Technologies is a healthcare company that develops, manufactures, and distributes point-of-care diagnostic tests and specimen collection devices.

Market cap

$272.64M+14.3%

Revenue$113.0M-30.1%

Net income-$75.1M-135%

Free cash flow-$47.9M-3,347%

EPS (diluted)-$1.04-148%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$27.9MBeat by $209.1K EPS-$0.32Miss by $0.09

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$28.9M

EPS estimate-$0.27

Financials

Q1 2026

Income statement

See full

Revenue$27.9M-6.7%

Gross profit$11.8M-4.0%

Operating income-$23.3M-31.1%

Net income-$22.4M-39.5%

EPS (diluted)-$0.32-52.4%

Balance sheet

See full

Cash & equivalents$177.0M-28.5%

Total debt$12.7M-10.9%

Total equity$313.3M-20.9%

Total assets$379.2M-17.1%

Cash flow

See full

Operating cash flow-$13.9M+29.6%

CapEx$913.0K+117%

Free cash flow-$14.8M+26.5%

Valuation & ratios

Valuation

See full

Market cap$272.64M+14.3%

Enterprise value$108.34M+260%

P/S2.4×+0.6×

Profitability

See full

Gross margin42.2%+0.4pp

Operating margin-68.6%-149pp

Net margin-66.4%-115pp

FCF margin-42.4%-43.3pp

Returns & leverage

See full

Return on equity-21.2%-50.4pp

Debt / equity0×0.0×

Current ratio5.5×-6.9×

Segments

By product

See full

HIV$13.0M+0.9%

Sample Management Solutions$9.1M-0.6%

HCV$2.7M-38.5%

Other Product And Services Revenues$1.6M+109%

Non-product and services revenues$1.5M+65.8%

By geography

See full

Africa$6.8M-5.8%

Europe$1.4M-11.5%

Other regions$1.0M+33.8%

Competitors

By market cap

Abbott$182.00B-17.2%

Danaher$138.14B-4.9%

Becton, Dickinson and Company$43.8B-16.5%

Revvity$12.1B+7.6%

Bio-Rad Laboratories$8.5B+22.9%

QuidelOrtho Corporation$1.1B-35.0%

OraSure Technologies$272.6M+8.8%

ADV

Advanced Biomed Inc. Common Stock$23.7M+106%

By revenue growth

Abbott+8.1%

Becton, Dickinson and Company+6.4%

Revvity+4.8%

Danaher+4.6%

Bio-Rad Laboratories+1.9%

QuidelOrtho Corporation-3.9%

OraSure Technologies-30.1%

By net margin

Danaher15.95%+1.7pp

Abbott11.65%-20.8pp

Revvity8.26%-2.1pp

Bio-Rad Laboratories6.52%+91.7pp

Becton, Dickinson and Company5.33%-2.1pp

QuidelOrtho Corporation-45.57%-32.6pp

OraSure Technologies-66.42%-46.6pp

Profile

OraSure Technologies is a healthcare company that develops, manufactures, and distributes point-of-care diagnostic tests and specimen collection devices. The company specializes in decentralizing healthcare by providing actionable insights through rapid testing for infectious diseases and advanced sample management solutions for genomics and microbiome research. Its value proposition centers on easy-to-use, non-invasive technologies that enable testing in both professional clinical settings and at-home consumer environments.

Competitive position

A leading provider of oral-fluid diagnostic tests and the first to market with several WHO-prequalified self-tests for HIV and HCV.

GeographiesUnited States, Europe, Canada, Global

Customer segmentsHealthcare Providers, Research Institutions, Government Agencies, Retail Consumers

Business modelManufacturing, Direct-to-consumer, B2B Distribution

SuppliersRaw material suppliers for chemical reagents, Medical-grade plastic manufacturers, Automated manufacturing equipment providers

CustomersRetail pharmacies, Diagnostic laboratories, Public health clinics, Research universities, E-commerce platforms

CountryUnited States of America

Listed1986

Employees638.0

CEOCarrie Eglinton Manner

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websiteorasure.com

FilingsSEC EDGAR

Ask your AI about OraSure Technologies.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OraSure Technologies's market cap?: OraSure Technologies (OSUR) has a market capitalization of $272.6M and trades on NASDAQ.
What is OraSure Technologies's revenue and profitability?: OraSure Technologies generated $113.0M in trailing twelve-month revenue with a net loss of $75.1M, representing a net margin of -66.4%. Gross margin stands at 42.2%, with free cash flow of -$47.9M. These figures are based on the Q1 2026 filing.
Who are OraSure Technologies's competitors?: OraSure Technologies's key competitors include QuidelOrtho, Abbott Laboratories, Danaher Corporation, and others. These companies compete in similar markets and product categories.
Who does OraSure Technologies partner with?: OraSure Technologies's notable partners include Walmart, Amazon, Diagnostics Direct, and others.
What subsidiaries does OraSure Technologies have?: OraSure Technologies's subsidiaries include BioMedomics, Inc., Sherlock.
Where is OraSure Technologies headquartered?: OraSure Technologies is headquartered in United States of America and employs approximately 638 people. It has been publicly traded since 1986.